Two cases of refractory IgG4-related disease successfully treated with tocilizumab

Ann Hematol. 2022 Jul;101(7):1593-1594. doi: 10.1007/s00277-022-04787-x. Epub 2022 Feb 13.

Authors

Jeremy Ong¹, Susan Brown², Michael Gilbertson^{2

3}, George Grigoriadis^{2

3}, Ian Simpson⁴, Shahla Vilcassim^{2

3}, Michael Low^{2

3}, Pasquale Fedele^{2

3}, Olga Motorna², Lynden Roberts^{3

5}, Michael Gingold⁵, Gareth Gregory^{2

3}

Affiliations

¹ Department of Haematology, Monash Health, Clayton, VIC, Australia. Jeremy.Ong@monashhealth.org.
² Department of Haematology, Monash Health, Clayton, VIC, Australia.
³ School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
⁴ Department of Anatomical Pathology, Monash Health, Clayton, VIC, Australia.
⁵ Department of Rheumatology, Monash Health, Clayton, VIC, Australia.

PMID: 35152313
DOI: 10.1007/s00277-022-04787-x

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Immunoglobulin G4-Related Disease* / diagnosis
Immunoglobulin G4-Related Disease* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
tocilizumab